AriBio Co., Ltd.

2 clinical trials · Sponsor

Record	Firm	Date
Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD) (NCT05531526)	AriBio Co., Ltd.	2022-12-23
Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease (NCT03625622)	AriBio Co., Ltd.	2019-04-01

Every clearance here is in the API, with alerts when new ones post.